Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Treatment Clinical Trials for Non-Small Cell Lung Cancer

Review the non-small cell lung cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 476

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Status: Active
Location: 1051 locations
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Status: Active
Location: 431 locations
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 419 locations
Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Status: Active
Location: 556 locations
Comparing Impact of Treatment Before or After Surgery in Patients with Stage II-IIIB Resectable Non-small Cell Lung Cancer
Status: Active
Location: 344 locations
Chemotherapy Combined with Immunotherapy versus Immunotherapy alone for Older Adults with Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Status: Active
Location: 294 locations
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People with Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment with Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 260 locations
Targeted Treatment for Advanced Non-Small Cell Lung Cancer that has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 242 locations
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients with Cancer That Has Spread to the Brain
Status: Active
Location: 225 locations
Testing Osimertinib as a Treatment for Lung Cancers with an EGFR Exon 20 Change
Status: Active
Location: 245 locations
Targeted Treatment for Advanced Non-Small Cell Lung Cancer that Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 202 locations
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy with or without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients who are PD-L1 Negative
Status: Active
Location: 151 locations
Immunotherapy after Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Status: Active
Location: 147 locations
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
Status: Active
Location: 134 locations
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients with Non-Small Cell Lung Cancer
Status: Active
Location: 93 locations
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Status: Active
Location: 56 locations
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Location: 42 locations
Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer, The STABLE-MATES Trial
Status: Active
Location: 29 locations
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Status: Active
Location: 34 locations
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Status: Active
Location: 34 locations
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) during Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
Status: Active
Location: 28 locations
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Active
Location: 27 locations
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
Status: Active
Location: 25 locations
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Status: Active
Location: 21 locations
Testing Targeted Radiotherapy while Continuing Ongoing Immunotherapy (with or without Chemotherapy) versus Switching to a Different Chemotherapy for Metastatic Non-small Cell Lung Cancer
Status: Active
Location: 18 locations